Tirzepatide, Emerging Drug Insight and Market Forecast – 2032

Tirzepatide, Emerging Drug Insight and Market Forecast – 2032

“Tirzepatide, Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about Tirzepatide for Obesity in the 7MM. A detailed picture of the Tirzepatide for Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Tirzepatide for Obesity. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Tirzepatide market forecast, analysis for Obesity in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Obesity.

Drug Summary

Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. Tirzepatide is currently in phase III development for adults with obesity or overweight who have weight-related comorbidity, and it is currently under regulatory review as a treatment for adults with type 2 diabetes.It is also being studied as a potential treatment for Non-alcoholic Steatohepatitis (NASH) and Heart Failure with Preserved Ejection Fraction (HFpEF). Tirzepatide studies in Obstructive Sleep Apnea (OSA) and morbidity and mortality in obesity are also planned.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the Tirzepatide description, mechanism of action, dosage and administration, research and development activities in Obesity.

Elaborated details on Tirzepatide regulatory milestones and other development activities have been provided in this report.

The report also highlights the Tirzepatide research and development activity in Obesity in detail across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around Tirzepatide.

The report contains forecasted sales of Tirzepatide for Obesity till 2032.

Comprehensive coverage of the late-stage emerging therapies for Obesity.

The report also features the SWOT analysis with analyst views for Tirzepatide in Obesity.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Tirzepatide Analytical Perspective by DelveInsight

In-depth Tirzepatide Market Assessment

This report provides a detailed market assessment of Tirzepatide in Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Tirzepatide Clinical Assessment

The report provides the clinical trials information of Tirzepatide in Obesity covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Obesity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Tirzepatide dominance.

Other emerging products for Obesity are expected to give tough market competition to Tirzepatide and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Tirzepatide in Obesity.

Our in-depth analysis of the forecasted sales data of Tirzepatide from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Tirzepatide in Obesity.

Key Questions

What is the product type, route of administration and mechanism of action of Tirzepatide?

What is the clinical trial status of the study related to Tirzepatide in Obesity and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Tirzepatide development?

What are the key designations that have been granted to Tirzepatide for Obesity?

What is the forecasted market scenario of Tirzepatide for Obesity?

What are the forecasted sales of Tirzepatide in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Obesity and how are they giving competition to Tirzepatide for Obesity?

Which are the late-stage emerging therapies under development for the treatment of Obesity?